Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

Bio-Techne’s 21% return over the past six months has outpaced the S&P 500 by 10.9%, and its stock price has climbed to $62.36 ...

How Does Total Compensation For Chuck Kummeth Compare With Other Companies In The Industry? At the time of writing, our data shows that Bio-Techne Corporation has a market capitalization of US$13b, ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...

In an effort to boost production of materials used in cell and gene therapy, Minneapolis-based life sciences company Bio-Techne Corp. is spending up to $50 million to create a new manufacturing ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...

With its stock down 6.6% over the past month, it is easy to disregard Bio-Techne (NASDAQ:TECH). However, stock prices are usually driven by a company’s financials over the long term, which in this ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...